Lilly's guidance increase — from $82-85 billion to $85-87 billion — signals that demand for its obesity and diabetes medications is running ahead of expectations. The move was the stock’s largest single-day gain in months, and the move came as part of a broader earnings season in which GLP-1 makers have repeatedly beaten forecasts. The market's message is simple: this class of medication is a permanent, expanding part of American healthcare.
For stone patients, the expansion raises a practical question that the market coverage rarely touches: what happens to kidney-protective nutrition when a medication suppresses appetite?
Appetite suppression changes eating in ways that matter for stones. When appetite drops, calcium intake can fall if dairy disappears from the plate — and low calcium raises oxalate stone risk. Fluid intake can also drop, because thirst and hunger signals blur, and concentrated urine is the primary stone risk. And rapid weight loss has been associated in some research with shifts in urine chemistry, including uric acid spikes.
Patients on GLP-1s benefit from a defined check-in schedule, because the eating pattern changes over weeks as appetite settles. A useful rhythm: a 24-hour urine collection before starting or early in treatment to establish a baseline, then a repeat after weight stabilizes or after any dose change. The test shows whether the dairy-first plan is actually protecting calcium and citrate, or whether adjustment is needed. Weight, blood pressure, and kidney function markers (creatinine, eGFR) belong on the same schedule, because GLP-1s and their side effects interact with both.
The practical framing for patients: the medication is a tool, and the stone diet is the structure the tool operates inside. A patient who treats the GLP-1 as the whole answer — eating whatever fits the small appetite — misses the calcium and hydration that the stone plan provides. The patient who runs the medication inside the measured structure gets the weight benefit
Finally, a note on the broader GLP-1 evidence: the medications themselves are not stone drugs, and the research on stones and GLP-1s is still developing. What the stone literature already knows is that rapid weight change and appetite suppression are the two variables to manage. The dairy-first, water-on-schedule structure addresses both directly. Patients who keep that structure in place while the medication does its work are following the evidence on both sides —
And for patients considering GLP-1s who have never had a stone evaluation, the starting point is a conversation with the care team, not the pharmacy. Knowing the stone type and the baseline urine chemistry before starting changes how the diet should be structured around the medication. A patient who establishes the baseline first can measure the medication's effects on the stone-relevant markers rather than guessing. The GLP-1 expansion is making this a routine conversation;
The GLP-1 era is also reshaping the food environment around patients — more diet foods, more protein-focused products, more weight-loss messaging. The stone-aware response is to let the measured table, not the marketing, decide what belongs on the plate. The comparison is the whole GLP-1-era lesson in miniature: the market sells convenience, and the measured table sells the actual nutrient. The patient who reads the oxalate column before the marketing copy gets the same satiety with the kidneys intact.A protein bar that promises satiety but carries 72 mg of oxalate is a marketing win and a stone-relevant cost; a Greek yogurt that delivers protein, calcium, and near-zero oxalate is the measured version of the same need. The medication wave makes the fundamentals — dairy, water, measured portions — more important, not less.
stone patients should have it early. the weight side and the stone side — at once. without trading away kidney protection. The measured response protects the fundamentals while the medication does its work: dairy at every meal, water on a schedule independent of thirst, protein in small frequent portions, and high-oxalate foods measured rather than eliminated.Because appetite is small, every bite must carry calcium or protein. A workable pattern: Greek yogurt at breakfast; a small chicken or egg salad with cheese at lunch; a palm-sized fish or tofu portion with broccoli at dinner; and water on a schedule — a bottle at each meal and a refill between. Even when only half a meal is eaten, the dairy-first ordering protects calcium first.
| Food | Oxalate (mg) | Serving | Rating |
|---|---|---|---|
| Greek yogurt, plain | 0 | 1 cup | Safe |
| Milk, cow's | 0 | 1 cup | Safe |
| Cheddar cheese | 0 | 1 oz | Safe |
| Chicken breast, roasted | 0 | 4 oz | Safe |
| Broccoli, boiled | 4 | 1/2 cup | Safe |
| Tofu, firm | 10 | 1/2 cup | Safe |
Not directly, but the eating changes it causes can. Appetite suppression can reduce calcium and fluid intake, and rapid weight loss has been associated with shifts in urine chemistry in some research. The stone-aware version protects dairy, water, and measured portions through the weight-loss process.
Dairy first, in small portions that fit a small appetite: Greek yogurt, milk, string cheese, cottage cheese. These deliver 200-400 mg of calcium at zero oxalate, and dairy before other foods protects the calcium line even when appetite is minimal.
Set a schedule rather than relying on thirst, because appetite suppression can blur thirst signals. A practical target: a glass at each meal plus refills between, enough to keep urine pale through the day. The urine-color check is the daily gauge.
And for the family members of GLP-1 patients: the support that helps most is practical, not editorial — stocking the dairy, keeping water visible, and joining the protein-first meals without comment. The patient manages the medication; the household manages the environment. Together they protect the fundamentals that the stone diet requires.
And that is the practical summary: the medication changes appetite; the measured structure protects the kidneys. Keep the dairy, keep the water, keep the portions — and let the market debate the rest.
See how oxalate values are measured and verified on our data methodology page.